Skip Nav Destination
The burden of heavy menstrual bleeding
Tackling ALK-positive LBCL
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism
The burden of heavy menstrual bleeding
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
Issue Archive
Table of Contents
Blood Commentaries
The burden of heavy menstrual bleeding
Clinical Trials & Observations
Tackling ALK-positive LBCL
Clinical Trials & Observations
Plenary Paper
Lenalidomide promotes the development of TP53-mutated therapy-related myeloid neoplasms
Clinical Trials & Observations
Adam S. Sperling,Veronica A. Guerra,James A. Kennedy,Yuanqing Yan,Joanne I. Hsu,Feng Wang,Andrew T. Nguyen,Peter G. Miller,Marie E. McConkey,Vanessa A. Quevedo Barrios,Ken Furudate,Linda Zhang,Rashmi Kanagal-Shamanna,Jianhua Zhang,Latasha Little,Curtis Gumbs,Naval Daver,Courtney D. DiNardo,Tapan Kadia,Farhad Ravandi,Hagop Kantarjian,Guillermo Garcia-Manero,P. Andrew Futreal,Benjamin L. Ebert,Koichi Takahashi
Clinical Trials and Observations
Incidence and impact of anticoagulation-associated abnormal menstrual bleeding in women after venous thromboembolism
CME
Clinical Trials & Observations
C. M. M. de Jong,M. Blondon,C. Ay,A. Buchmuller,J. Beyer-Westendorf,J. Biechele,L. Bertoletti,G. Colombo,M. P. Donadini,S. V. Hendriks,L. Jara-Palomares,S. Nopp,P. Ruiz-Artacho,P. Stephan,C. Tromeur,T. Vanassche,P. E. Westerweel,F. A. Klok,for the TEAM-VTE investigators
The burden of heavy menstrual bleeding
Clinical Trials & Observations
Hematopoiesis and Stem Cells
A macaque clonal hematopoiesis model demonstrates expansion of TET2-disrupted clones and utility for testing interventions
Tae-Hoon Shin,Yifan Zhou,Shirley Chen,Stefan Cordes,Max Z. Grice,Xing Fan,Byung-Chul Lee,Aisha A. Aljanahi,So Gun Hong,Kelli L. Vaughan,Julie A. Mattison,Steven G. Kohama,Margarete A. Fabre,Naoya Uchida,Selami Demirci,Marcus A. F. Corat,Jean-Yves Métais,Katherine R. Calvo,Manuel Buscarlet,Hannah Natanson,Kathy L. McGraw,Alan F. List,Lambert Busque,John F. Tisdale,George S. Vassiliou,Kyung-Rok Yu,Cynthia E. Dunbar
Immunobiology and Immunotherapy
Lymphoid Neoplasia
Loss of COP9 signalosome genes at 2q37 is associated with IMiD resistance in multiple myeloma
Brief Report
Sarah Gooding,Naser Ansari-Pour,Mohammad Kazeroun,Kubra Karagoz,Ann Polonskaia,Mirian Salazar,Evie Fitzsimons,Korsuk Sirinukunwattana,Selina Chavda,Maria Ortiz Estevez,Fadi Towfic,Erin Flynt,William Pierceall,Daniel Royston,Kwee Yong,Karthik Ramasamy,Paresh Vyas,Anjan Thakurta
Letters to Blood
Next-generation ALK inhibitors are highly active in ALK-positive large B-cell lymphoma
Clinical Trials & Observations
Jacob D. Soumerai,Allison Rosenthal,Shannon Harkins,Jessica Duffy,Carmen Mecca,Yingbing Wang,Ravinder K. Grewal,Areej R. El-Jawahri,Huiyun Liu,Cedric Menard,Ahmet Dogan,Lei Yang,Lisa M. Rimsza,Kurt Bantilan,Haley Martin,Matthew Lei,Sydney Mohr,Anna Kurilovich,Olga Kudryashova,Ekaterina Postovalova,Valentina Nardi,Jeremy S. Abramson,Roberto Chiarle,Andrew D. Zelenetz,Abner Louissaint, Jr.
Blood Work
Continuing Medical Education (CME) Questions
-
Cover Image
Cover Image
A hematoxylin and eosin–stained tumor from a patient-derived xenograft model of anaplastic lymphoma kinase (ALK)–positive large B-cell lymphoma shows sheets of malignant cells with plasmablastic morphology and frequent mitotic figures. The model was used to show the therapeutic activity of next-generation ALK inhibitors. See the article by Soumerai et al on page 1822
- PDF Icon PDF LinkFront Matter
- PDF Icon PDF LinkTable of Contents
- PDF Icon PDF LinkBack Matter
- PDF Icon PDF LinkEditorial Board
Advertisement intended for health care professionals
Email alerts
Advertisement intended for health care professionals
Connecting the dots: lenalidomide and t-MNs